Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, said investor discussions have increasingly focused on Vertex’s expanding pipeline beyond cystic fibrosis, particularly its renal franchise. She […]